Syneron Bio announced the completion of a $150 million Series B financing round, strengthening its position as a developer of intelligent platform-driven macrocyclic peptide therapeutics and accelerating its push toward clinical development.
The financing was led by an international life sciences fund, with co-lead participation from Decheng Capital and CDH VGC. Additional backing came from a subsidiary of the Abu Dhabi Investment Authority, True Light Capital, Qiming Venture Partners, BioTrack Capital, and other institutional investors. Existing investors, including AstraZeneca, LAV, Sinovation Capital, 5Y Capital, GL Ventures, Biotech Development Fund, and Lenovo Capital, also participated in the round.
The company plans to use the proceeds to advance its proprietary Synova platform, which focuses on intelligent, high-throughput macrocyclic peptide discovery. Funding will also support the continued development of its pipeline targeting oncology, autoimmune, metabolic, and rare diseases, with the goal of moving multiple programs into clinical stages.
Syneron Bio is positioning its platform as a next-generation approach to drug discovery, leveraging data-driven, AI-enabled processes to improve efficiency and success rates in identifying viable therapeutic candidates. The company indicated that the additional capital will enable it to further scale the platform while expanding its global development efforts.
KEY QUOTE:
“We are honored to receive support and recognition in this financing round from a distinguished group of leading global healthcare funds, tech venture capitals, reputable multi national corporations, and prominent sovereign wealth funds. The completion of this financing further strengthens our cash position, enabling us to accelerate the development of multiple core pipeline programs across oncology, autoimmune, metabolic, and rare diseases, with the goal of benefiting patients worldwide. At the same time, our high throughput, intelligence driven Synova platform will continue to scale and evolve, significantly improving the efficiency and success rate of macrocyclic peptide drug discovery. With the continued support of our capital and industry partners, we look forward to delivering innovative therapies and addressing critical unmet medical needs for patients around the globe.”
Dr. Frank Zhang, Founder And Chief Executive Officer Of Syneron Bio
